Eli Lilly blows past estimates, hikes sales outlook on resilient Zepbound and Mounjaro demand — Live Feedhttps://www.live-feeds.com/feed/eli-lilly-blows-past-estimates-hikes-sales-outlook-on-resilient-zepbound-and-mounjaro-demandContinuously updated, source-cited coverage. Eli Lilly raises sales outlook on strong Zepbound and Mounjaro demandhttps://www.live-feeds.com/feed/eli-lilly-blows-past-estimates-hikes-sales-outlook-on-resilient-zepbound-and-mounjaro-demandhttps://www.live-feeds.com/feed/eli-lilly-blows-past-estimates-hikes-sales-outlook-on-resilient-zepbound-and-mounjaro-demand#u166711Sun, 01 Nov 2026 04:17:32 +0000Eli Lilly reported stronger-than-expected Q3 2026 results, driven by resilient demand for its diabetes treatment Mounjaro and obesity drug Zepbound. The company raised its full-year sales outlook, citing regulatory progress and growth in the metabolic health segment. Lilly's revenue climbed on surging sales of these two blockbuster drugs.Why it mattersEli Lilly's performance is significant in the pharmaceutical industry, particularly in the areas of diabetes and obesity treatment. The company's success with Mounjaro and Zepbound has positioned it as a leader in the metabolic hea